Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study of EGFR806 CAR T-Cell Immunotherapy for Treating Children and Young Adults with Recurrent/Refractory Solid Tumors

Trial Status: active

This phase I trial studies side effects and best dose of EGFR806-specific and EGFR806xCD19 CAR T cells and how well they work in treating patients with solid tumors that have come back (recurrent) or do not respond to treatment (refractory). T cells are a type of immune cell that can recognize proteins on the surface of other cells and then target and kill cells that have that protein. Some solid tumor cells have an EGFR protein on their surface, and T cells can be modified with a receptor, called a chimeric antigen receptor (CAR), to help recognize this protein and kill these tumor cells; this is the treatment in Arm A of this study. In Arm B of this study, researchers will modify T cells to recognize EGFR as well as a protein called CD19; CD19 is present on the surface of a group of normal white blood cells called B cells. Researchers hypothesize that modifying T cells to be directed against CD19 in addition to EGFR may act as an additional signal to help the T cells directed against EGFR to grow better and last longer.